Ming-Kai Chen

List of Publications by Year
in descending order

52 papers	2,885 citations	318942 23 h-index	274796 44 g-index
54 all docs	54 docs citations	54 times ranked	3969 citing authors

#	Article	IF	Citations
1	Determining the Minimal Required Ultra-Low-Dose CT Dose Level for Reliable Attenuation Correction of[18]F-FDG PET/CT: A Phantom Study. Journal of Nuclear Medicine Technology, 2022, 50, 126-131.	0.4	0
2	PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 766-770.	2.7	6
3	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. Neurobiology of Aging, 2022, 111, 44-53.	1.5	25
4	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCBâ€J. Alzheimer's and Dementia, 2022, 18, 2527-2536.	0.4	55
5	Deep learningâ€"based attenuation correction for whole-body PET â€" a multi-tracer study with 18F-FDG, 68ÂGa-DOTATATE, and 18F-Fluciclovine. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3086-3097.	3.3	8
6	Imaging of Synaptic Density in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 60S-67S.	2.8	29
7	Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation task. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1067-1079.	2.4	28
8	Association of AÎ² deposition and regional synaptic density in early Alzheimerâ€™s disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research and Therapy, 2021, 13, 11.	3.0	53
9	Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimerâ€™s disease: A tracer kinetic modeling study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2395-2409.	2.4	43
10	Generation of synthetic PET images of synaptic density and amyloid from [18]Fâ€FDG images using deep learning. Medical Physics, 2021, 48, 5115-5129.	1.6	12
11	Generation of parametric K_i images for FDG PET using two 5â€min scans. Medical Physics, 2021, 48, 5219-5231.	1.6	16
12	Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease. NeuroImage, 2021, 238, 118248.	2.1	17
13	Synthesizing Multi-tracer PET Images for Alzheimerâ€™s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. Lecture Notes in Computer Science, 2021, , 34-43.	1.0	6
14	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
15	Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB. International Journal of Obesity, 2020, 44, 964-967.	1.6	18
16	Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCBâ€J positron emission tomography study. Epilepsia, 2020, 61, 2183-2193.	2.6	51
17	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037791.	0.4	1
18	ICAâ€derived sources of synaptic density PET ([11 C]UCBâ€J) relate to cognitive impairment severity in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041197.	0.4	3

#	Article	IF	Citations
19	Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracer PET study. Alzheimer's and Dementia, 2020, 16, e043631.	0.4	0
20	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044211.	0.4	2
21	Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [11 C]UCB‐J PET. Alzheimer's and Dementia, 2020, 16, e045928.	0.4	1
22	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's and Dementia, 2020, 16, 974-982.	0.4	170
23	PET imaging of mGluR5 in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 15.	3.0	29
24	Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET. EJNMMI Physics, 2020, 7, 67.	1.3	45
25	Effects of age, BMI and sex on the glial cell marker TSPO â€" a multicentre [11C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	3.3	70
26	Neuroimaging in Dementias. Seminars in Neurology, 2019, 39, 188-199.	0.5	14
27	P4â€481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497.	0.4	0
28	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	0.4	0
29	Kinetic evaluation and testâ€"retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 2041-2052.	2.4	143
30	P2â€365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P832.	0.4	0
31	P1â€469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P501.	0.4	1
32	ICâ€04â€03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.	0.4	0
33	ICâ€Pâ€183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P152.	0.4	0
34	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology, 2018, 75, 1215.	4.5	304
35	Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics in Medicine and Biology, 2018, 63, 175015.	1.6	17
36	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 353-357.	3.3	44

#	Article	IF	Citations
37	Imaging synaptic density in the living human brain. Science Translational Medicine, 2016, 8, 348ra96.	5.8	343
38	Determining the Minimal Required Radioactivity of ^{18}F-FDG for Reliable Semiquantification in PET/CT Imaging: A Phantom Study. Journal of Nuclear Medicine Technology, 2016, 44, 26-30.	0.4	11
39	What is the role of dosimetry in patients with advanced thyroid cancer?. Current Opinion in Oncology, 2015, 27, 33-37.	1.1	8
40	Use of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography to aid in diagnosing intestinal adenocarcinoma in 2 rhesus macaques (Macaca mulatta). Comparative Medicine, 2014, 64, 211-20.	0.4	0
41	The Utility of I-123 Pretherapy Scan in I-131 Radioiodine Therapy for Thyroid Cancer. Thyroid, 2012, 22, 304-309.	2.4	57
42	Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Current Opinion in Oncology, 2010, 22, 6-10.	1.1	8
43	VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 78-90.	2.1	111
44	Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair. , 2008, 118, 1-17.		428
45	Manganese inhibits NMDA receptor channel function: Implications to psychiatric and cognitive effects. NeuroToxicology, 2007, 28, 1147-1152.	1.4	66
46	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. NeuroImage, 2006, 33, 550-563.	2.1	42
47	Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Experimental Neurology, 2006, 202, 381-390.	2.0	170
48	Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. NeuroToxicology, 2006, 27, 229-236.	1.4	87
49	Imaging the Peripheral Benzodiazepine Receptor Response in Central Nervous System Demyelination and Remyelination. Toxicological Sciences, 2006, 91, 532-539.	1.4	61
50	Evidence for Cortical Dysfunction and Widespread Manganese Accumulation in the Nonhuman Primate Brain following Chronic Manganese Exposure: A 1H-MRS and MRI Study. Toxicological Sciences, 2006, 94, 351-358.	1.4	110
51	In Vivo Imaging of Peripheral Benzodiazepine Receptors in Mouse Lungs: A Biomarker of Inflammation. Molecular Imaging, 2005, 4, 7290.2005.05133.	0.7	33
52	Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain, 2004, 127, 1379-1392.	3.7	124